Drug
LY3300054 clinical trials
Also written LY3300054.
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2017
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
3 studies that test it; most in 2017 (2)
| Year | Studies |
|---|---|
| 2017 | 2 |
| 2018 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 2 · Other 1
Eli Lilly and Company (2) · Dana-Farber Cancer Institute (1)
Often tested with
Tested in the same studies.
LY3321367 (1) · Prexasertib (1)
Studies
Open first, then newest update. How each study uses LY3300054 is read from its arms, and is right about nine times in ten.
Testing it · 3
- A Study of LY3321367 Alone or With LY3300054 in Participants With Advanced Relapsed/Refractory Solid TumorsCompletedPhase 1Eli Lilly and CompanyNCT03099109Written as LY3300054
- A Study of Prexasertib (LY2606368), CHK1 Inhibitor, and LY3300054, PD-L1 Inhibitor, in Patients With Advanced Solid TumorsCompletedPhase 1Dana-Farber Cancer InstituteNCT03495323Written as LY3300054
- A Study of LY3381916 Alone or in Combination With LY3300054 in Participants With Solid TumorsTerminatedPhase 1Eli Lilly and CompanyNCT03343613Written as LY3300054
Given in every arm · 2 — LY3300054 is usual care beside what is tested
- A Study of LY3200882 in Participants With Solid TumorsActive, not recruitingPhase 1Eli Lilly and CompanyNCT02937272Written as LY3300054
- A Study of Anti-PD-L1 Checkpoint Antibody (LY3300054) Alone and in Combination in Participants With Advanced Refractory Solid TumorsCompletedPhase 1Eli Lilly and CompanyNCT02791334Written as LY3300054